FDA Approves ILUMYA for Adults With Active Psoriatic Arthritis
Paul Pickrell, MD, and Tekton’s Austin team supported INSPIRE 1, one of the Phase 3 studies behind ILUMYA’s new approval for active psoriatic arthritis.
Advancing Medicine
Clinical Trials Day 2026: The People Behind the Progress
Every treatment, therapy, and medical breakthrough begins with people. People willing to ask questions. People willing to care deeply. People willing to show up every day to move medicine forward. This Clinical Trials Day, we’re celebrating the people behind the progress at Tekton Research: the coordinators, investigators, site managers, nurses, recruiters, business development professionals, and … Read more
World Obesity Day: Changing the Narrative Through Research
Today is World Obesity Day – a moment to pause and reflect on one of the fastest-growing global health challenges of our time. More than 1 billion people worldwide are currently living with obesity. By 2035, that number is expected to rise significantly, with nearly half of the global population projected to be living with … Read more
Welcoming Dr. Arti Thangudu to Tekton Research
Tekton Research is pleased to welcome Dr. Arti Thangudu as a Principal Investigator in San Antonio, Texas, further strengthening our growing network of physician-led clinical research sites. Dr. Thangudu is a triple board-certified physician in Endocrinology, Diabetes & Metabolism, and Internal Medicine, bringing more than a decade of clinical experience to her role. As the … Read more
Case Study: GLP-1 Medication Research Study
Tekton met enrollment goals for a GLP-1 study in Moore, OK three months early, with a one-day regulatory turnaround.
Case Study: Phase 2 Migraine Research Study
Tekton delivered a Phase 2 migraine study in Yukon, OK with 100% patient retention and a 1.5-day regulatory turnaround.
Tekton Research Expands with Three New Sites, Five New Investigators, and CNS Thought Leader
Growth supports Tekton’s strategic focus on CNS and Cardiometabolic research AUSTIN, TX – September 26, 2025 — Tekton Research, a leading multi-site clinical trial company, is proud to announce the addition of three new sites, five new Principal Investigators (PIs), and a renowned CNS Consultant to its expanding network. These additions reflect Tekton’s continued commitment … Read more
Why Rare Disease Trials Are Different: Challenges and Opportunities
When it comes to clinical research, no two studies are exactly alike—but rare disease trials stand in a category of their own. Though each condition may affect only a small number of people, together rare diseases impact an estimated 300 million patients worldwide. For these individuals and families, research often represents the only pathway to … Read more
How Clinical Trials Are Powering the Future of Alzheimer’s Care
Alzheimer’s Disease remains one of the most pressing public health challenges of our time. Affecting over 6 million Americans, this progressive neurological disorder not only takes a profound toll on individuals and their families–it also places a significant burden on healthcare systems worldwide. While there is no cure yet, hope is on the horizon–and clinical … Read more
How Obesity Impacts Chronic Diseases: A Closer Look
Obesity is more than a number on a scale–it’s a chronic disease that significantly increases the risk of developing long-term health conditions. At Tekton Research, we’re committed to advancing research in obesity because we know it’s at the core of a larger health crisis. Understanding and treating obesity isn’t just about weight loss, it’s about … Read more